Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press25810.17650/1994-4098-2010-0-3-95-100GYNECOLOGY. TREATMENTГИНЕКОЛОГИЯ. ЛЕЧЕНИЕClear cell endometrial carcinoma: analysis of the results of a 20-year follow-upСветлоклеточная карцинома эндометрия: анализ результатов 20-летнего наблюденияLaktionovK. P.ЛактионовК. П.
Russian Federation
AbdullayevaG. M.АбдуллаеваГ. М.
Russian Federation
AnurovaO. A.АнуроваО. А.
Russian Federation
19627777@mail.ruGadzhiyevaS. M.ГаджиеваС. М.
Russian Federation
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowГУ РОНЦ им. Н.Н. Блохина РАМН, Москва2808201039510028082014280820142010https://ojrs.abvpress.ru/ojrs/article/view/258

The paper presents data on the clinical and morphological characteristics, clinical presentation, and treatment of clear cell carcinoma, as well as survival rates in patients with this condition. It shows an association of the expression of the intercellular adhesion molecules E-cadhedrin, α- and β-catenins, the molecule of Her-2/neu with the clinical and morphological pattern of the disease, which has been determined by an immunohisto- chemical assay.

В статье представлены данные клинико-морфологической характеристики, клинического течения, лечения и выживаемости пациенток со светлоклеточной карциномой. Показана связь экспрессии молекул межклеточной адгезии Е-кадхерина, α- и β-катенинов, молекулы Her-2/neu с особенностями клинико-морфологической картины заболевания, установленная при проведении иммуногистохимического исследования.

endometrial carcinomaclear cell endometrial carcinomaprognosismetastasestreatmentрак эндометриясветлоклеточная карцинома эндометрияпрогнозметастазылечение1. Craighead P.S., Sait K., Gavin C.S. et al. Management of aggressive histologic variants of endometrial carcinoma at the Tom Baker Cancer Centre between 1984 and 1994. Gynecol Oncol 2000;77:248–53.Craighead P.S., Sait K., Gavin C.S. et al. Management of aggressive histologic variants of endometrial carcinoma at the Tom Baker Cancer Centre between 1984 and 1994. Gynecol Oncol 2000;77:248–53.2. Toft D., Gorski J.A. Receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. Proc Nat Acad Sci USA 1966;55(6):1574–81.Toft D., Gorski J.A. Receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. Proc Nat Acad Sci USA 1966;55(6):1574–81.3. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–81.Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–81.4. Cowles T.A., Magrina J.F., Masterson B.J. Comparison of clinical and surgical staging in patients with endometrial carcinoma. Obstet Gynecol 1985;66(3):413–6.Cowles T.A., Magrina J.F., Masterson B.J. Comparison of clinical and surgical staging in patients with endometrial carcinoma. Obstet Gynecol 1985;66(3):413–6.5. Abeler V.M., Vergote I.B., Kjorstad K.E. et al. Clear-cell carcinoma of the endometrium. Prognostic and metastatic pattern. Cancer 1996;78:1740–7.Abeler V.M., Vergote I.B., Kjorstad K.E. et al. Clear-cell carcinoma of the endometrium. Prognostic and metastatic pattern. Cancer 1996;78:1740–7.6. Murphy K.T., Rotmensch J., Yamada S.D. et al. Outcome and patterns of failure in pathologic stages I–IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 2003;55(5):1272–6.Murphy K.T., Rotmensch J., Yamada S.D. et al. Outcome and patterns of failure in pathologic stages I–IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 2003;55(5):1272–6.7. Ульрих Е.А., Нейштадт Э.Л. Редкие формы рака тела матки. Практ онкол 2004;5(1).Ульрих Е.А., Нейштадт Э.Л. Редкие формы рака тела матки. Практ онкол 2004;5(1).8. Васильева Е.В., Белианин В.Л. Серозная аденокарцинома: критерии морфологического диагноза и иммуногистохимия. Арх патол 2005;67(2):25–7.Васильева Е.В., Белианин В.Л. Серозная аденокарцинома: критерии морфологического диагноза и иммуногистохимия. Арх патол 2005;67(2):25–7.9. Pitson G., Colgan T., Levin W. et al. Stage II endometrial carcinoma: prognostic factors and risk classification in 170 patients. Int J Radiat Oncol Biol Phys 2002;15;53(4):862–7.Pitson G., Colgan T., Levin W. et al. Stage II endometrial carcinoma: prognostic factors and risk classification in 170 patients. Int J Radiat Oncol Biol Phys 2002;15;53(4):862–7.10. Нечушкина В.М., Кузнецов В.В., Лазарева Н.И. и др. Современные представления о лечении рака тела матки. Сиб онкол журн 2007;65–8.Нечушкина В.М., Кузнецов В.В., Лазарева Н.И. и др. Современные представления о лечении рака тела матки. Сиб онкол журн 2007;65–8.11. Wijnhoven B.P., Dinjens W.N., Pignatelli M. E-cadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg 2000;87(8):992–1005.Wijnhoven B.P., Dinjens W.N., Pignatelli M. E-cadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg 2000;87(8):992–1005.12. Stefansson I.M., Salvensen H.B., Akslen L.А. Prognostic impact of alterations in P-cadherin expressionStefansson I.M., Salvensen H.B., Akslen L.А. Prognostic impact of alterations in P-cadherin expressionand related cell adhesion markers in endometrial cancer. J Clin Oncol 2004;22:1242–52.13. Athanassiadou P., Athanassiades P., Grapsa D. et al. The prognostic value of PTEN, p53 and β-catenin in endometrial carcinoma: a prospective immunocytochemical study. Int Gynecol Cancer 2007;697–704.Athanassiadou P., Athanassiades P., Grapsa D. et al. The prognostic value of PTEN, p53 and β-catenin in endometrial carcinoma: a prospective immunocytochemical study. Int Gynecol Cancer 2007;697–704.14. Kim Y.T., Choi E.K., Kim J.W. et al. Expression of E-cadherin and £-, β-, γ- catenin proteins in endometrial carcinoma. Yonsei Med J 2002;43:701–11.Kim Y.T., Choi E.K., Kim J.W. et al. Expression of E-cadherin and £-, β-, γ- catenin proteins in endometrial carcinoma. Yonsei Med J 2002;43:701–11.15. Cirisano F.D., Robboy S.J., Dodge R.K. et al. The outcome of stage I–II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol 2000;77:55–65.Cirisano F.D., Robboy S.J., Dodge R.K. et al. The outcome of stage I–II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol 2000;77:55–65.16. Carey M.S., O'Connell G.J., Johanson C.R. et al. Good outcome associated with a standardized treatment protocol using selective postoperative 2 radiation in patients with clinical stage I adenocarcinoma of the endometrium. Gynecol Oncol 1995;57(2):138–44.Carey M.S., O'Connell G.J., Johanson C.R. et al. Good outcome associated with a standardized treatment protocol using selective postoperative 2 radiation in patients with clinical stage I adenocarcinoma of the endometrium. Gynecol Oncol 1995;57(2):138–44.17. Marchetti D.L., Caglar H., Driscoll D.L. et al. Pelvic radiation in stage I endometrial adenocarcinoma with high-risk attributes. Gynecol Oncol 1990;37(1):51–4.Marchetti D.L., Caglar H., Driscoll D.L. et al. Pelvic radiation in stage I endometrial adenocarcinoma with high-risk attributes. Gynecol Oncol 1990;37(1):51–4.18. Smith R.S., Peters W.A., Drescher C.W. Cisplatin, doxorubicin hydrochloride and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma. Am J Obstet Gynecol 1994;170:1677–82.Smith R.S., Peters W.A., Drescher C.W. Cisplatin, doxorubicin hydrochloride and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma. Am J Obstet Gynecol 1994;170:1677–82.19. Ткачева Н.Ю. Рецепторы прогестерона в матке в норме и при опухолевом росте. Автореф. дис. ... канд. мед. наук. М., 1994.Ткачева Н.Ю. Рецепторы прогестерона в матке в норме и при опухолевом росте. Автореф. дис. ... канд. мед. наук. М., 1994.20. Trope C., Kristensen G.B., Abeler V.M. Clear-cell and papillary serous cancer: treatment options. Baillieres. Best Pract Res Clin Obstet Gynecol 2001;15(3):433–46.Trope C., Kristensen G.B., Abeler V.M. Clear-cell and papillary serous cancer: treatment options. Baillieres. Best Pract Res Clin Obstet Gynecol 2001;15(3):433–46.21. Abeler V.M., Vergote I.B., Kjorstad K.E. et al. Clear-cell carcinoma of the endometrium. PrognosticAbeler V.M., Vergote I.B., Kjorstad K.E. et al. Clear-cell carcinoma of the endometrium. Prognosticand metastatic pattern. Cancer 1996;78(8):1740–7.